Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 143 | Longs Won 58/126 46% | Profit Factor 1.37 |
| Profitability | Shorts Won 9/17 52% | Standard Deviation $6,555.1 |
| Average Win $4,725.76 | Best Trade (Aug 10) $32,604.95 | Sharpe Ratio -58.64 |
| Average Loss -$3,031.8 | Worst Trade (Oct 16) -$30,632.46 | Z-Score -3.49 (100%) |
| Commissions $0 | Avg. Trade Length 2m 4w 1d | Expectancy $602.86 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | 0.03% | 0.21% | 0.9% | 2.84% | 7.24% | 15.99% | 31.76% | 58.19% |
| Consecutive Losing Trades | 62 | 55 | 49 | 43 | 37 | 31 | 25 | 18 | 12 | 6 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
PTGX Protagonist Therapeutics Inc. | 1,445.61 | $216,841.38 | $186,208.92 | - | -$30,632.46 | -14.13% | -5.668% |